DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for autism — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutism maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autism is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
eukaryotic translation initiation factor 4E (EIF4E) — EIF4E is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet mgpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5T46 · 1.53 Å · ligand 7-METHYL-GUANOSINE-5'-TRIPHOSPHATE (MGP). Experimental structure, not a prediction.
What the evidence adds up to
A 2008 review of comprehensive early intervention trials for children with autism found that only Lovaas’s treatment met formal criteria for a “well-established” intervention; no treatment met the “probably efficacious” standard, and three treatments met the “possibly efficacious” threshold. Most studies were rated as Type 2 or Type 3 in methodological rigour. The review noted that randomised controlled trials have shown positive effects on developmental functioning and reductions in maladaptive behaviours and symptom severity at the group level, but it remains unknown whether these changes translate into improved independence or vocational and social functioning in adulthood. The authors concluded that the field is still at an early stage in determining which interventions are most efficacious, what variables moderate or mediate outcomes, and what degree of short-term and long-term improvement can reasonably be expected.
A 2014 paper using systems biology and network analyses claimed to shed light on the molecular and cellular mechanisms underlying autism, but provided no clinical data, no drug tested, and no patient outcomes. Another 2014 publication, despite its title referencing uninsured populations in Thailand, discussed the difficulty of measuring treatment response in children with autism spectrum disorder due to the heterogeneity and subtlety of symptom changes over short periods. It called for continued development of outcome measures to help identify and compare efficacious interventions.
No drug treatment for autism is tested or reported in any of these abstracts. The evidence base for early behavioural interventions remains limited in scope and rigour, and no trial has demonstrated that any intervention alters long-term adult outcomes. What is still missing are large, well-controlled trials with standardised outcome measures that can detect meaningful change over years, adequate funding for such trials, and a way to stratify patients by the biological subtypes that network analyses are only beginning to propose.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Child & Adolescent Psychology · 2008 · 978 citations · open access
Evidence-Based Comprehensive Treatments for Early Autism
AbstractEarly intervention for children with autism is currently a politically and scientifically complex topic. Randomized controlled trials have demonstrated positive effects in both short-term and longer term studies. The evidence suggests that early intervention programs are indeed beneficial for children with autism, often improving developmental functioning and decreasing maladaptive behaviors and symptom severity at the level of group analysis. Whether such changes lead to significant improvements in terms of greater independence and vocational and social functioning in adulthood is also unknown. Given the few randomized controlled treatment trials that have been carried out, the few models that have been tested, and the large differences in interventions that are being published, it is clear that the field is still very early in the process of determining (a) what kinds of interventions are most efficacious in early autism, (b) what variables moderate and mediate treatment gains and improved outcomes following intervention, and (c) the degree of both short-term and long-term improvements that can reasonably be expected. To examine these current research needs, the empirical studies of comprehensive treatments for young children with autism published since 1998 were reviewed. Lovaas's treatment meet Chambless and colleague's (Chambless et al., 1998; Chambless et al., 1996) criteria for "well-established" and no treatment meets the "probably efficacious" criteria, though three treatments meet criteria for "possibly efficacious" (Chambless & Hollon, 1998). Most studies were either Type 2 or 3 in terms of their methodological rigor based on Nathan and Gorman's (2002) criteria. Implications of these findings are also discussed in relation to practice guidelines as well as critical areas of research that have yet to be answered.
BMC Psychiatry · 2012 · 63 citations · open access
Long-term oxytocin administration improves social behaviors in a girl with autistic disorder
AbstractBACKGROUND: Patients with autism spectrum disorders (ASDs) exhibit core autistic symptoms including social impairments from early childhood and mostly show secondary disabilities such as irritability and aggressive behavior based on core symptoms. However, there are still no radical treatments of social impairments in these patients. Oxytocin has been reported to play important roles in multiple social behaviors dependent on social recognition, and has been expected as one of the effective treatments of social impairments of patients with ASDs. CASE PRESENTATION: We present a case of a 16-year-old girl with autistic disorder who treated by long-term administration of oxytocin nasal spray. Her autistic symptoms were successfully treated by two month administration; the girl's social interactions and social communication began to improve without adverse effects. Her irritability and aggressive behavior also improved dramatically with marked decreases in aberrant behavior checklist scores from 69 to 7. CONCLUSION: This case is the first to illustrate long-term administration of oxytocin nasal spray in the targeted treatment of social impairments in a female with autistic disorder. This case suggests that long-term nasal oxytocin spray is promising and well-tolerated for treatment of social impairments of patients with ASDs.
The Journal of Clinical Psychiatry · 2016 · 2 citations · open access
Does the Clinical Benefit of Ketamine Treatment Offer Any Clues to Autism Spectrum Disorder Etiology?
AbstractArticle AbstractBecause this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.To the Editor: Wink et al reported the first case study demonstrating clinical improvement in mood and eye fixation scores from intranasal ketamine treatment in a "complicated" subject with autism spectrum disorder (ASD). Arnold et al recently highlighted perioperative differences among patients with or without ASD, finding that the most salient difference was the use of premedication types. ASD patients were 3 times more likely to use nonstandard premedicants (eg, intramuscular ketamine) versus standard medications (eg, midazolam).
Molecular Systems Biology · 2014 · 1 citations · open access
Autism cornered: network analyses reveal mechanisms of autism spectrum disorders
AbstractDespite a wealth of behavioral, cognitive,biological, and genetic studies, the causes of autism have remained largely unknown.In their recent work, Snyder and colleagues(Li et al, 2014) use a systems biology approach and shed light on the molecular and cellular mechanisms underlying autism, thus opening novel avenues forunderstanding the disease and developing potential treatments.
Situation of the Uninsured in Khon Kaen Municipal area, 2005(สภาพขอเทจจรงทเกยวของกบผไมมสทธหลกประกนสขภาพ ในเขตเทศบาลนครขอนแกน ป 2548)
AbstractSignificant advancements have been made in early intervention programs for children with Autism spectrum disorder (ASD). However, measuring treatment response for children with ASD is difficult due to the heterogeneity of changes in symptoms, which can be subtle, especially over a short period of time. Here we outline the challenge of evaluating treatment response with currently available measures as well as newly developed or refined measures that may be useful in clinical trials for young children with ASD. Continued development of treatment outcome measures will help the field identify and compare efficacious interventions and tailor treatments for children with ASD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
